Acadian Asset Management
MRVI icon

Acadian Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Acadian Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,905
Closed -$74K – 1976
2024
Q3 		$74K Buy
+8,905
New +$77K ﹤0.01% 1694
2021
Q2 		– Sell
-8,773
Closed -$312K – 2141
2021
Q1 		$312K Buy
+8,773
New +$291K ﹤0.01% 1352

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management's MRVI Position: Q4 2024 in Review

Acadian Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 8,905 shares — an estimated $74K sold.

Acadian Asset Management first reported a position in MRVI in Q1 2021 and held it in 2 quarters. The position peaked at $312K in Q1 2021. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Acadian Asset Management reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 8,905 Maravai LifeSciences shares in Q4 2024, an estimated $74K.
  • Acadian Asset Management first reported a position in Maravai LifeSciences in Q1 2021 and held it in 2 quarters.
  • Acadian Asset Management's Maravai LifeSciences position peaked at $312K in Q1 2021.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.